Synlogic stock.

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Continue Reading. September 28, 2023. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Continue Reading. September 27, 2023. Synlogic Announces Reverse Stock Split. Continue Reading. September 21, 2023. Synlogic to Participate in Chardan’s Genetic Medicines Conference.CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Synlogic Inc () Stock Market info Recommendations: Buy or sell Synlogic stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Synlogic share forecasts, stock quote and buy / sell signals below.According to present data Synlogic's SYBX shares and potentially its market environment have been in a bullish …

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

$-12.72 Market Cap $18.29 M Shares Outstanding 9.19 M Public Float 4.54 M Yield SYBX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short …Institutional investors have sold a total of 13,539,674 shares in the last 24 months. This volume of shares sold represents approximately $97.33M in transactions. Iterum Therapeutics Institutional Ownership. This page (NASDAQ:SYBX) was last updated on 11/16/2023 by MarketBeat.com Staff.The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term ...Mar 17, 2022 · Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ... Nov 9, 2017 · Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs.

When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...

Find the latest Synlogic Inc (MINA.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.

TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comNov 9, 2023 · Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information. ١٦‏/٠٥‏/٢٠١٧ ... ... stock ticker was the real bounty Synlogic sought. The companies expect to complete their deal sometime in the third quarter. The merged ...Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone.Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17.So, it ...Synlogic and Mirna Therapeutics Agree to Merger. May 16, 2017. PDF Version. – Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines –. – Synlogic Closes $42 Million of Series C Preferred Stock Financing by LeadingBiotechnology Investors –.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Nov 24, 2023 · Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? SYBX: 0.8376 (-3.60%) ROIV: 5.14 (-2.10%) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks PR Newswire - Thu Aug 11, 6:05AM CDT

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. …Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI.

Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. “Last year was a tremendous year for …CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.You may vote if you were the record owner of Synlogic, Inc. common stock at the close of business on April 18, 2023 (the “Record Date”). A list of registered stockholders as of the close of business on the Record Date will be available at our corporate headquarters for examination by any stockholder for any purpose germane to the Annual Meeting for a …The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. You may vote if you were the record owner of Synlogic, Inc. common stock at the close of business on April 18, 2023 (the “Record Date”). A list of registered stockholders as of the close of business on the Record Date will be available at our corporate headquarters for examination by any stockholder for any purpose germane to the Annual Meeting for a …0A8U Stock Overview. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).

You may vote if you were the record owner of Synlogic, Inc. common stock at the close of business on April 18, 2023 (the “Record Date”). A list of registered stockholders as of the close of business on the Record Date will be available at our corporate headquarters for examination by any stockholder for any purpose germane to the Annual Meeting for a …Ginkgo Bioworks. 11 Aug, 2022, 07:05 ET. SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic. CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 ...Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs.Nov 30, 2023 · View Synlogic, Inc SYBX investment & stock information. Get the latest Synlogic, Inc SYBX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Founded Date 2014. Founders Alison Silva, Ankit Mahadevia, Dean Falb, Jim Collins, Timothy K. Lu. Operating Status Closed. Last Funding Type Post-IPO Equity. Legal Name Synlogic, Inc. Stock Symbol NASDAQ:SYBX. Company Type For Profit. Contact Email [email protected]. Phone Number (617)401-9975.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the company’s Phase 2 Synpheny-1 study for phenylketonuria (PKU) were presented in a podium presentation yesterday during the …

Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.Synlogic (NASDAQ:SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27.The reverse stock split is primarily intended to bring the ...Instagram:https://instagram. vanguard 2050 fundoanda vs metatrader 4best dental coverage in californiabest annuity rates Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ... stocks to buy now 2023jp morgan advisory fees Synlogic, Inc. (NASDAQ:SYBX) climbed 9.7% to $0.55 in pre-market trading. Synlogic announced the FDA granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria. Losers good stocks buy now $-12.72 Market Cap $18.29 M Shares Outstanding 9.19 M Public Float 4.54 M Yield SYBX is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short …Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.Synlogic ( NASDAQ: SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27. The reverse stock split is primarily intended to bring the ...